Main menu
Edison Group
  • Home
  • Equities

    Equities

    View All Equities

    Equities by Sector

    AGBA

    MCap

    USD93m

    Last close

    USD2.50

    ▲ 1.25 (100.00%)

    Pharnext

    MCap

    1m

    Last close

    EUR0.10

    ▲ 0.03 (42.86%)

    MGI – Media and Games Invest

    MCap

    EUR235m

    Last close

    EUR1.50

    ▲ 0.35 (30.21%)

  • Sectors

    Sectors

  • Investment Strategy

    Investment Strategy

    View All

    Latest

  • Thematics

    Thematics

    View All Thematics

    Latest

  • Audiovisual

    Audiovisual

    View All Audiovisual

    Latest

Shield Therapeutics (AIM: STX)

Last close As at 22/04/2024

GBP0.02

▲ −0.05 (−3.16%)

Market capitalisation

13m

Edison Investment Research is terminating coverage on Shield Therapeutics (STX). Please note you should no longer rely on any previous research or estimates for this company. All forecasts should now be considered redundant.

Latest Insights

View More

Healthcare | Flash note

Shield Therapeutics — New CFO to support US traction

Healthcare | Flash note

Shield Therapeutics — Delivering what the doctor ordered

Healthcare | Update

Shield Therapeutics — Ramped up and heading into a stronger H223

Healthcare | Update

Shield Therapeutics — FY23 a key year for business traction
Laboratory
Visit Website

Sector

Healthcare

Balance Sheet

Forecast net debt (US$m)

N/A

Forecast gearing ratio (%)

N/A

Share Price Performance

Price Performance
% 1M 3M 12M
Actual (37.6) (79.1) (73.3)
Relative (39.7) (79.9) (74.1)
52 week high/low 12.5p/1.6p

Financials

Edison Investment Research is terminating coverage on ABC Arbitrage (ABCA), paragon (PGN), Foresight Solar Fund (FSFL), Kendrion (KENDR), Lithium Power International (LPI), Triple Point Energy Transition (TENT), 4iG (4IG), e-therapeutics (ETX), Pharnext (ALPHA) and Shield Therapeutics (STX). Please note you should no longer rely on any previous research or estimates for this company. All forecasts should now be considered redundant.

Previously published reports can still be accessed via our website.

Y/E Dec Revenue (US$m) EBITDA (US$m) PBT (US$m) EPS (fd) (c) P/E (x) P/CF (x)
2021A N/A N/A N/A N/A N/A N/A
2022A 5.5 (28.7) (31.2) (12.3) N/A N/A
2023E N/A N/A N/A N/A N/A N/A
2024E N/A N/A N/A N/A N/A N/A

Research

Laboratory

Flash note

Healthcare

Shield Therapeutics — Delivering what the doctor ordered

Update

Healthcare

Shield Therapeutics — Ramped up and heading into a stronger H223
Laboratory

Healthcare

Flash note

Shield Therapeutics — New CFO to support US traction

Laboratory
View All

Thematics

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free